关键词: 缺血性心肌病, 2型糖尿病, 炎症因子, 心功能, 心率变异性

Abstract:

Objective： The purpose of this research is to investigate the effects of semaglutide combined with rosuvastatin on blood glucose， lipids， inflammatory factors， cardiac function， HRV in type 2 diabetes patients with ischemic cardiomyopathy.Methods： 180 type 2 diabetes patients with ischemic cardiomyopathy admitted to our hospital from October 2022 to October 2023 were selected. Using a randomized controlled method， patients were divided into an experimental group and a control group， with 90 cases in each group. The control group received conventional drugs combined with rosuvastatin， while the experimental group received semaglutide on the basis of the control group. Compare the changes in blood glucose， lipid levels， inflammatory factors， cardiac function， and heart rate variability indicators between two groups before and after treatment. We detected blood glucose， lipids， inflammatory factors， cardiac function， HRV before and after treatment in each group.Results： After treatment， the levels of blood glucose， blood lipids， and inflammatory factors were all improved in both groups with statistical differences （P<0.05）； Compared with the control group， the levels of FPG， 2-hour PBG， and HbA1c in the experimental group were significantly reduced after treatment with statistical differences （P<0.05）； The levels of TG， TC， and LDL-C in the experimental group were significantly reduced， while the levels of HDL-C were significantly increased with statistical differences （P<0.001）； The levels of CRP and IL-6 in the experimental group were significantly reduced （both P<0.05）， but there is no statistically significant difference in TNF-α levels between the two groups （P >0.05）. After treatment， the levels of LVEF， CRP， SDNN， SDANN， PNN50， and RMSSD were significantly increased in both groups with statistical differences （P<0.05）； After treatment， the heart rate variability indicators （SDNN， SDANN， PNN50， and RMSSD） of the experimental group were significantly increased with statistical differences （P<0.001）， while there was no statistically significant difference in LVEF levels between the two groups （P>0.05）.Conclusion： Semaglutide combined with rosuvastatin has a significant therapeutic effect on type 2 diabetes patients with ischemic cardiomyopathy， which can effectively regulate glucose and lipid metabolism， reduce inflammatory reaction， and improve cardiac function and heart rate variability

Key words: Ischemic cardiomyopathy； , Type 2 diabetes； , Inflammatory factors； , Heart function； , Heart rate variability